Korea's regulator approved Hanmi Pharmaceutical's efpeglenatide, the first homegrown GLP-1 obesity drug, after patients lost 9.02% of body weight in 40 weeks. That is less than Wegovy and Mounjaro showed in longer trials, so Hanmi's case rests on milder side effects and a price for long-term patients that it has not yet set.
Reality
- Evidence60
- Adoption
- Insufficient
- Hype gap+20
- Incentives55
- Confidence58
Hanmi Pharmaceutical's Eppe could launch in Korea before year-end at an estimated 150,000 won for four weeks, 45% below Mounjaro's cheapest listing. Lilly won about 85% of the market at a higher price than Wegovy, so Novo, which has cut once already, is the likelier incumbent to cut again.
Reality
- Evidence45
- Adoption
- Insufficient
- Hype gap+25
- Incentives
- Insufficient
- Confidence40
AriBio's October Phase 3 readout for AR1001 decides whether Fosun Pharma adds $80 million to the $60 million option fee it paid in May. Among the Korean biotech events due that month, it is the one that ties a partner's cash directly to trial data.
Reality
- Evidence40
- Adoption
- Insufficient
- Hype gap+20
- Incentives70
- Confidence45
The FDA is investigating whether GLP-1 drugs cause sudden vision loss, and the New Jersey filings number in the dozens. The market those drugs sell into is projected at $92 billion this year.
Reality
- Evidence45
- Adoption74
- Hype gap+14
- Incentives62
- Confidence42
Thirty of Korea's most exposed drugmakers raised first-half R&D by about a fifth as next year's generic price cuts approach, and the two largest spenders in the group supplied most of the increase. Four smaller firms cut.
Reality
- Evidence62
- Adoption58
- Hype gap+16
- Incentives70
- Confidence58
Two out-licensing deals in three months put 375.8 billion won of upfront cash on Hanmi's books, about 1.5 times last year's operating profit, and it was the obesity candidate still in Phase 1 that priced richest.
Reality
- Evidence48
- Adoption68
- Hype gap+34
- Incentives66
- Confidence54
Combined first-half research spending reached 562.8 billion won. Chong Kun Dang's 37% jump supplied nearly 40% of the group's increase, and the filings carry no profit lines to weigh it against.
Reality
- Evidence68
- Adoption62
- Hype gap+14
- Incentives72
- Confidence60